THERAPY DOSSIER · th-b8756265da33

gp91ds-tat (NOX2-specific inhibitor peptide)

Drug · gp91ds-tat is a NOX2 (NADPH oxidase 2)-specific inhibitor peptide (research tool); no confident ChEMBL name match returned

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: gp91ds-tat is a NOX2 (NADPH oxidase 2)-specific inhibitor peptide (research tool); no confident ChEMBL name match returned
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26377802 ↗2015Reported benefit

Inhibition of NOX2 reduces locomotor impairment, inflammation, and oxidative stress after spinal cord injury.

MouseSpinal cord injuryContusionC57BL/6MaleIntrathecal injectionImmediately after impact

Model: Moderate spinal cord contusion injury

gp91ds-tat significantly improved functional recovery through 28 days post-injury, reduced inflammatory cell concentrations in the injured cord at 24 hours and 7 days, and reduced oxidative stress and M1 polarisation marker expression at 24 hours.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…